|527.25||-1.21||-0.23%||Vol 74.51K||1Y Perf 102.77%|
|Apr 16th, 2021 10:41 DELAYED|
|- -%||- -|
|Target Price||581.25||Analyst Rating||Strong Buy 1.50|
|Potential %||10.29||Finscreener Ranking||★★★ 51.35|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★+ 45.15|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 69.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||45.15B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||85.28||Earnings Date||4th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|10 Years||1 228.79%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2021|
|Estimated EPS Next Report||1.72|
|EPS Growth Next 5 Years %||15.80|
|Avg. Weekly Volume||316.67K|
|Avg. Monthly Volume||426.40K|
|Avg. Quarterly Volume||466.64K|
IDEXX Laboratories Inc. (NASDAQ: IDXX) stock closed at 528.46 per share at the end of the most recent trading day (a 2.78% change compared to the prior day closing price) with a volume of 438.73K shares and market capitalization of 45.15B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 9300 people. IDEXX Laboratories Inc. CEO is Jonathan J. Mazelsky.
The one-year performance of IDEXX Laboratories Inc. stock is 102.77%, while year-to-date (YTD) performance is 5.72%. IDXX stock has a five-year performance of 562.81%. Its 52-week range is between 256.42 and 573.99, which gives IDXX stock a 52-week price range ratio of 85.28%
IDEXX Laboratories Inc. currently has a PE ratio of 74.50, a price-to-book (PB) ratio of 67.69, a price-to-sale (PS) ratio of 20.85, a price to cashflow ratio of 66.90, a PEG ratio of 2.32, a ROA of 27.12%, a ROC of 39.71% and a ROE of 140.98%. The company’s profit margin is 22.77%, its EBITDA margin is 29.20%, and its revenue ttm is $2.08 Billion , which makes it $24.29 revenue per share.
Of the last four earnings reports from IDEXX Laboratories Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.72 for the next earnings report. IDEXX Laboratories Inc.’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for IDEXX Laboratories Inc. is Strong Buy (1.5), with a target price of $581.25, which is +10.29% compared to the current price. The earnings rating for IDEXX Laboratories Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IDEXX Laboratories Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IDEXX Laboratories Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.40, ATR14 : 20.16, CCI20 : 202.24, Chaikin Money Flow : 0.22, MACD : 0.69, Money Flow Index : 87.46, ROC : 10.28, RSI : 53.59, STOCH (14,3) : 97.22, STOCH RSI : 1.00, UO : 68.12, Williams %R : -2.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IDEXX Laboratories Inc. in the last 12-months were: Brian P. Mckeon (Option Excercise at a value of $7 876 851), Brian P. Mckeon (Sold 131 247 shares of value $54 270 553 ), Bruce L. Claflin (Option Excercise at a value of $1 476 124), Bruce L. Claflin (Sold 20 811 shares of value $9 111 786 ), Daniel M. Junius (Option Excercise at a value of $1 144 071), Daniel M. Junius (Sold 1 342 shares of value $1 505 469 ), Giovani Twigge (Option Excercise at a value of $4 796 935), Giovani Twigge (Sold 65 026 shares of value $25 823 011 ), James F. Polewaczyk (Option Excercise at a value of $1 312 407), James F. Polewaczyk (Sold 16 264 shares of value $4 860 515 ), Jonathan J. Mazelsky (Option Excercise at a value of $1 599 925), Jonathan J. Mazelsky (Sold 18 774 shares of value $9 750 203 ), Jonathan W. Ayers (Option Excercise at a value of $12 396 427), Jonathan W. Ayers (Sold 539 846 shares of value $180 172 097 ), Kathy V. Turner (Option Excercise at a value of $0), Kathy V. Turner (Sold 2 690 shares of value $809 690 ), M. Anne Szostak (Option Excercise at a value of $1 875 772), M. Anne Szostak (Sold 27 320 shares of value $10 555 655 ), Michael J. Lane (Option Excercise at a value of $202 184), Michael J. Lane (Sold 2 154 shares of value $1 040 920 ), Nimrata Hunt (Option Excercise at a value of $130 629), Nimrata Hunt (Sold 4 874 shares of value $2 034 169 ), Rebecca M. Henderson (Option Excercise at a value of $2 712 073), Rebecca M. Henderson (Sold 35 740 shares of value $11 816 682 ), Sharon E. Underberg (Option Excercise at a value of $199 904), Sophie V. Vandebroek (Option Excercise at a value of $488 213), Sophie V. Vandebroek (Sold 3 046 shares of value $1 639 357 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.